Diagnosis, management and screening of early localised prostate cancer.

Selley, Sara; Donovan, JL; Faulkner, Alex; Coast, Joanna; Gillatt, David

doi:10.3310/hta1020

Cited by 94 publications

(73 citation statements)

References 321 publications

(800 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSA screening is not recommended in the UK [13,14]. However, this is a controversial subject, with many men believing it is in their interests to have a PSA test [15].…”

Section: Introductionmentioning

confidence: 99%

Pathways to the diagnosis of prostate cancer in a British city. A population-based study

Barrett¹,

Hamilton

2005

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…PSA screening is not recommended in the UK [13,14]. However, this is a controversial subject, with many men believing it is in their interests to have a PSA test [15].…”

Section: Introductionmentioning

confidence: 99%

Pathways to the diagnosis of prostate cancer in a British city. A population-based study

Barrett¹,

Hamilton

2005

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…The incidence rate returned to or near the 1988 baseline in the following years. However, some American physicians still hesitate to apply PSA testing for mass screening, since its effectiveness in decreasing the mortality and morbidity of prostate cancer remains to be proved (55,56). On the other hand, mass or individual screening by serum PSA assay is not recommended by the Oncology Committee of the French Association of Urology (57).…”

Section: Screeningmentioning

confidence: 99%

Prostate-Specific Antigen and New Related Markers for Prostate Cancer

Daher¹,

Beaini²

1998

CCLM

View full text Add to dashboard Cite

Although prostate-specific antigen (PSA), or human kallikrein 3, is the most valuable tool available for the diagnosis and management of prostate cancer, as currently used it is insufficiently sensitive and specific for early detection or staging of the malignancy. Many new concepts have been introduced in order to optimize the clinical use of PSA measurements, but each one has its own drawbacks. The molecular forms of PSA, especially the free PSA, seem to be useful for the detection of prostate cancer in men with PSA concentrations falling in the 4-10 microg/l range. New molecular techniques, such as reverse transcriptase polymerase chain reaction for the detection of minimal amounts of PSA messenger RNA and prostate-specific membrane antigen, offer new promise for the prognosis and possibly staging of prostate cancer. On the other hand, human kallikrein 2, a serine protease closely related to PSA that is also expressed predominantly in the prostate, may be a new adjuvant marker for prostate cancer. As for its biological functions, PSA can no longer be regarded as a specific prostate molecule associated mainly with semen liquefaction when it has a possible role as a prognostic indicator in female breast cancer. The biological role of PSA in normal tissues and tumors may be much more complex than previously thought and requires further investigation.

show abstract

“…[16][17][18][19][20][21] Although bowel cancer fulfills all of the criteria needed to qualify for consideration of population screening, 22 it is important to learn from the problems incurred by other screening programs. [23][24][25][26][27][28][29] Cervical Screening ''Much effort...is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur.... No matter how obvious its predicted benefit...introduction should never take place without...evaluation of the positive and negative effects in controlled trials.'' 26 Breast Screening ''...allocation of limited resources...on a proposed mass population intervention must be based on a critical analysis of benefits, harm, and cost.…”

mentioning

confidence: 99%